Samsung Bioepis Partners With Yuhan On Korean Adalimumab
Marketing Partnership Agreed For Adalloce Biosimilar Rival To Humira
Samsung Bioepis has added its Adalloce adalimumab version of Humira to its Korean biosimilars partnership with Yuhan Corporation, ahead of an imminent launch.
